Targeting intraepithelial lymphocytes for treatment of metabolic syndrome
AssigneeThe General Hospital Corporation
InventorsFilip K. Swirski, Shun He
Life of this patent
Estimating the term…
Abstract
Methods and compositions of treating patients with metabolic syndrome or a disease associated with metabolic syndrome using inhibitors that target natural intraepithelial lymphocytes.
Claims21
A method of reducing risk of developing metabolic syndrome or a disease associated with metabolic syndrome in a subject with a family history of metabolic syndrome or a disease associated with metabolic syndrome, elevated blood pressure, dysglycemia, or abdominal obesity, the method comprising administering a therapeutically effective amount of a β7 integrin inhibitor to the subject in need thereof.
A method of treating a subject who has been diagnosed with metabolic syndrome or a disease associated with metabolic syndrome, the method comprising administering a therapeutically effective amount of a β7 integrin inhibitor to the subject in need thereof.
A method of reducing risk of developing metabolic syndrome or a disease associated with metabolic syndrome in a subject with family history of metabolic syndrome or a disease associated with metabolic syndrome, elevated blood pressure, dysglycemia, or abdominal obesity, the method comprising administering a therapeutically effective amount of a CCR9 inhibitor or a GLP-1 agonist to the subject in need thereof.
Dependencies are inferred from the claim text.